Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UP-FOR-U: Upadacitinib for recurrent anterior uveitis in axial spondyloarthritis
2025-522118-21-00Phase 4Authorised
- Sponsor
- CARE Arthritis
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 4, open-label trial of upadacitinib in axial spondyloarthritis (axSpA) and Acute Iridocyclitis (2 arms), sponsored by CARE Arthritis. Primary endpoint: Change in exposure-adjusted acute anterior uveitis event rate. Planned start Mar 2026; status: authorised.
02
Drugs
upadacitinib
03
Conditions
axial spondyloarthritis (axSpA)Acute Iridocyclitis
Beyond the preview
Go deeper on 2025-522118-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522118-21-00.